Table 1 Baseline characteristics of the study population at CAISM/UNICAMP from 2000 to 2015
Characteristics | Median (%) |
|---|---|
Age (years) | 28 (13–46) |
Parity | 1 (0–9) |
Schooling years (n = 769) | |
  < 8 | 60.9 |
 8–11 yrs. | 32.2 |
  > 12 | 5.1 |
 No schooling | 1.8 |
Ethnicity: White | 61.2 |
HIV diagnosis (n = 789) | |
 Prior to pregnancy | 62.5 |
 During pregnancy | 37.5 |
In use of ART at conception (n = 787) | 27.6 |
In use of Efavirenz at conception (n = 793) | 10.2 |
Planned pregnancy (n = 382) | 25.7 |
Heterosexual transmission (n = 408) | 93.1 |
Baseline CD4 median (cells/mm3) | 444 (3–1915) |
Peripartum CD4 median (cells/mm3) | 552 (5–2164) |
Median time of ART use (days) | 152.5 (4–292) |
Median of detectable peripartum viral load (copies/ml) | 815 (43–500.000) |
Peripartum Viral Load < 50 (copies/ml) (n = 732) | 58.9 |
CDC classification (n = 758) | |
 1 | 29.9 |
 2 | 51.6 |
 3 | 18.5 |
Substance abuse (n = 568) | 14.3 |
Alcoholism (n = 528) | 5.7 |
Smoking (n = 538) | 14.1 |
ART adherence during prenatal care | 84.3 |
Changed ART (n = 776) | 19.2 |
Intravenous AZT (n = 775) | 94.8 |
Antiretroviral regimens during pregnancy (n = 793) | |
 None | 1.9 |
 AZT monotherapy | 2.9 |
 Dual therapy | 1.4 |
 2 NRTI + 1 NNRTI | 17.9 |
  AZT + 3TC + NVP | 16.8 |
  TDF + 3TC + NVP | 0.1 |
  d4T + 3TC + NVP | 0.5 |
  AZT + 3TC + EFV | 0.3 |
  TDF + 3TC + EFV | 0.3 |
 2 NRTI + 1 PI | 74.9 |
  AZT + 3TC + LPV/r | 48.5 |
  TDF + 3TC + LPV/r | 3.4 |
  d4T + 3TC + LPV/r | 0.1 |
  TDF + AZT + 3TC + LPV/r | 1.5 |
  AZT + 3TC + ATV/r | 1.8 |
  TDF + 3TC + ATV/r | 1.0 |
  ABC + 3TC + ATV/r | 0.1 |
  TDF + AZT + 3TC + ATV/r | 0.3 |
  AZT + 3TC + NFV | 16.8 |
  d4T + 3TC + NFV | 0.1 |
  2 NRTI + Other PI* | 1.3 |
 2 NRTI + PI** + RAL | 0.9 |
 2 NRTI + NNRTI + PI | 0.6 |
Total | 100 |